SAN DIEGO, CA – December 3, 2018 -- Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary portfolio includes Intravail®, ProTek® and Hydrogel™, three non-invasive drug delivery and stabilization technologies applicable to a wide-range of molecules including therapeutic proteins, peptides, non-peptide macromolecules and small molecules.
SAN DIEGO, CA – Sept. 25, 2018 -- Neurelis, Inc. today announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCOTM (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as cluster or acute repetitive seizures.
November 07, 2017 | Company developing NRL-1, a proprietary intranasal formulation of diazepam, for epilepsy patients who experience acute repetitive or cluster seizures
January 05, 2017 | Funds to be utilized to complete development work and begin commercialization preparations for NRL-1. Program has received Orphan Drug and Fast Track Designation from FDA.
January 04, 2017 | Neurelis Intranasal Diazepam Treatment For Epilepsy Granted Fast Track Designation By FDA
February 22, 2016 | The investment, led by LYZZ Capital, is intended to advance the company's lead program, NRL-1 (intranasal diazepam), through the remaining clinical work in preparation for FDA submission of a New Drug Application (NDA) in the US.
